Superworth

Orasure Technologies price to free cash flow OSUR

Market value divided by free cash flow over the last twelve months, since 2014.

Today, Oct 23, 2026
n/m
not a meaningful number
Last meaningful
9.5×
May 2025
10-year median
26.7×
10-year range
2.1× to 452×
Peer median
16.0×

Orasure Technologies' price to free cash flow is not a meaningful number today: free cash flow over the last twelve months was zero, negative or not reported.

It was last meaningful in May 2025, at 9.5×.

On the days it had one over the last ten years, its median was 26.7×, from 2.1× in Jul 2024 to 452× in Jul 2020.

Price to free cash flow over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
20259.5×4.1×11.1×
20244.2×2.1×6.0×
20236.1×4.8×64.0×
2022n/m a value too high to mean anything
2021n/m a value too high to mean anything
2020452×22.2×452×
201929.2×16.8×50.8×
201844.2×37.0×78.1×
201744.9×25.5×54.5×
201626.2×12.6×34.0×
201531.1×20.8×91.7×
201434.3×29.3×129×

Against its peers

Companies in Medical - Instruments & Supplies nearest Orasure Technologies' size, closest first, today.

CompanyPrice to free cash flow
OSUROrasure Technologiesn/m
INFUInfuSystem12.1×
UTMDUtah Medical Products20.6×
EMBCEmbecta2.3×
PDEXPro DEX29.5×
TCMDTactile Systems Technology20.0×
MDXGMimedxn/m
MOVMovado9.8×
KEQUKewaunee Scientific8.7×
IRMDIradimed43.7×
STAAStaar Surgicaln/m
Peer median16.0×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Orasure Technologies

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.